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Abstract
Background: Cell cycle checkpoint regulation is crucial for prevention of tumor in mammalian
cells. Cyclin-dependant kinase 4 (CDK4) is important in cell cycle regulation, as it controls the G1-
S phase of the cell cycle. CDK4 has potential mitogenic properties through phosphorylation of
target proteins. We aimed at identifying a role of CDK4 IVS4-nt40 G→A gene variant in benign and/
or malignant tumors and in obesity-associated benign and/or malignant tumors in an Italian adult
subject dataset.
Methods: We recruited 263 unrelated Italian subjects: 106 subjects had at least one benign tumor
and 46 subjects had at least one malignant tumor, while 116 subjects had at least two tumors and/
or cancers. We collected BMI data for 90% of them: 186 subjects had a BMI≥30 Kg/m2 and 52
subjects had a BMI ≥ 30 Kg/m2. We performed statistical power calculations in our datasets. DNA
samples were directly sequenced with specific primers for the CDK4 IVS4-nt40 G→A variant.
Genotype association tests with disease were performed.
Results: In our study, no significant association of the CDK4 IVS4-nt40 AA genotype with cancer
and/or tumors/cancer are/is detected. However, the CDK4 IVS4-nt40 AA genotype is significantly
associated with cancer and tumors/cancer in obese patients.
Conclusion: This finding is interesting since obesity is a risk factor for tumors and cancer. This
study should prompt further work aiming at establishing the role of CDK4 in contributing to tumor/
cancer genetic risk predisposition, as well as its role as a potentially effective therapeutic target
gene for obesity-associated tumor/cancer management.
Introduction
Cell cycle checkpoint functions regulate cell cycle progres-
sion and proliferation. Defects of cell cycle control are one
among hallmarks of tumor development and may have
relevance in tumor predisposition [1]. Cyclin-dependant
kinase 4 (CDK4) is an important gene for cell cycle regu-
lation, as it determines the number of cells entering the
G1 phase cell cycle [2]. It is located on chromosome
12q14 and the protein encoded within this gene is a mem-
ber of Ser/Thr protein kinase family. CDK4 has mitogenic
[2] through phosphorylation of target proteins [4]. The
chromosome 12q12-q14 region has been shown by a
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genome scan to be in linkage to bladder cancer [5], as well
as to obesity-associated type 2 diabetes genes [6]. Previous
studies have reported differential CDK4  expression in
tumors such as gliosarcoma, mantle cell lymphoma and
squamous cell carcinoma [7-9]. However, no study has up
to date investigated the CDK4  variant in the human
genome of cancer patients to prove their potential role in
oncogenic pathogenesis.
This study was carried out to find out whether there is any
association of CDK4  IVS4-nt40 G→A SNP with cancer
and/or tumors/cancer as well as with obesity-associated
cancer and/or tumors/cancer in the Italian population.
Materials and methods
We recruited from Italy a total of 263 unrelated adult sub-
jects from the general population. We carried out the
study with the written informed consent from each sub-
ject and with the approval from the Institutional Review
Board, in accordance with the Helsinki Declaration guide-
lines. We collected clinical information on the presence or
absence of tumors and/or cancer on the total 263 subjects.
Among 263 subjects, 152 subjects (58%) presented with
either benign and/or malignant tumors: among these, 106
subjects had at least one benign tumor and 46 subjects
had at least one malignant tumor, while 116 subjects had
at least two tumors and/or cancer. The various tumor and
cancer types are described in Table 1.
In the subject group, we collected BMI data for 90% of
subjects: 186 subjects had a BMI less than 30 Kg/m2 and
52 subjects had a BMI≥30 Kg/m2, thus the latter met the
definition for obesity.
DNA samples were directly sequenced by PCR and auto-
mated fluorescence sequencer with specific primers for
the  CDK4  IVS4-nt40 G→A single nucleotide polymor-
phism (SNP).
True detectable odds ratios (ORs) for genotype associa-
tion tests were calculated in our datasets with statistical
power at least 60%, type 1 error probability of 0.05, and
given, in the general Italian population, a cancer preva-
lence of 2.7% [10] and, in the obese Italian population, of
3.2% [11] (Table 2).
We tested the CDK4  IVS4-nt40 G→A SNP alleles for
departure from Hardy-Weinberg equilibrium (HWE) in
our cases (positive cancer and/or tumors/cancer) and con-
trol subjects (with no cancer and no tumors/cancer)
groups, separately, by using Chi-Square test statistics.
With the Mantel-Haenszel algorithm, we tested the CDK4
IVS4-nt40 G→A genotype variant for association with
cancer and with tumors/cancer against control subjects
with no cancer and no tumors/cancer, respectively. We
further tested the CDK4 IVS4-nt40 G→A at genotype level
for association with obesity-associated cancer and with
obesity-associated tumors/cancer against non-obese con-
trol subjects with no cancer and no tumors/cancer, respec-
tively.
We also perfomed an association test for non-obese can-
cer and tumors/cancer cases.
Results
All alleles tested in each group of the four datasets were
not in departure from HWE.
We did not identify in our dataset any significant and
valid association of the CDK4 IVS4-nt40 G→A genotype
variant with either cancer or tumors/cancer against con-
trol subjects with no cancer and no tumors/cancer, respec-
Table 1: Number of tumors/cancers types
Site Tumor Cancer
Skin 1 6
Oral cavity 1 1
RIT including lungs 2 2
GIT 8 8
Hormonal 67 22
Thyroid 29 1
Hematological 1 5
Brain 3 1
Endocrine 2 0
RIT = Respiratory tract, GIT = Gastrointestinal tract (liver, colon and 
pancreas), Hormonal-dependent = Breast, Ovary, Uterus, Prostate
Table 2: Statistical power calculated for genotype association 
test in each case-control dataset with α = 0.05
Subject groups Power Detectable OR
46 cases and 204 control subjects 65% 4.435
152 cases and 111 control subjects 65% 4.40
10 cases and 178 control subjects 65% 7.975
23 cases and 89 control subjects 60% 5.725
OR = odds ratioJournal of Experimental & Clinical Cancer Research 2009, 28:42 http://www.jeccr.com/content/28/1/42
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tively (Table 3, 4). However, our dataset may not be able
to detect any risk variant with a modest effect contributing
to cancer and/or tumors/cancer.
In the subset of the obesity-associated tumor/cancer anal-
ysis, we identified a significant association of the CDK4
IVS4-nt40 AA genotype with BMI ≥ 30 and cancer (P =
0.002, Table 5), and with BMI ≥ 30 and tumors/cancer (P
= 0.007, Table 6). We had in our datasets of genotype
association tests with the obesity-associated cancer and
obesity-associated tumors/cancer at least 60% power to
detect the risk ORs identified (Table 2). The analysis per-
formed to exclude association of the CDK4 IVS4-nt40 AA
genotype with the subset of non-obese cancer and
tumors/cancer was not significant.
Discussion
CDK4 is the catalytic subunit of the cyclin D-CDK holoen-
zyme. The kinase activity of this complex is induced in
response to extracellular signals, including growth factors,
and it translates signals from the extracellular environ-
ment into cell cycle activation [12]. The CDK4 gene lies in
a chromosomal region of interest for cancer predisposi-
tion [5] and for obesity-associated T2D genes [6]. It is
known to be involved in cell cycle regulation, and repre-
sents a strong candidate gene for tumor and/or cancer
genetic predisposition [13]. Although any potential gene
variant risk effect size in any tumor/cancer is not predict-
able until is tested, we can deduct from the present study
that the CDK4 IVS4-nt40 AA genotype does not independ-
ently and significantly contribute as a major significant
risk variant to tumors/cancer in our Italian dataset. If there
is any CDK4 variant risk effect in tumor and/or cancer pre-
disposition, it is likely too modest to be detected in the
current dataset. It is possible, however, that other CDK4
gene variants may potentially contribute to tumor/cancer
risk predisposition as well as that any potential CDK4 var-
iant association may be detected by using a larger dataset.
On the contrary, it should also be considered that the
tumor/cancer risk predisposition may be linked to the
obesity-factor. In fact, in our study, obese patients (BMI ≥
30) with CDK4 IVS4-nt40AA genotype have a significant
increased risk for tumors and cancers, in both datasets
tested. As we excluded any association of the CDK4 IVS4-
nt40 AA genotype with the subset of non-obese cancer
and tumor/cancer cases, we were able to further confirm
the validity of the identified association with the obese-
associated cancer and tumor/cancer cases.
Several studies report that obesity increases tumor/cancer
incidence [14,11,15,16]. From our study, we may con-
clude that CDK4 IVS4-nt40 AA genotype plays a role in
obesity-associated tumor/cancer risk predisposition.
However, more studies are warranted to establish the role
of other CDK4 variants in tumor-cancer predisposition
[5]. As obesity is a preventable associated factor in several
tumor and/or cancer types [14,11,15], both lifestyle mod-
Table 4: CDK4 IVS4-nt40G→A genotype association with tumor/cancer
Genotype 152 Tumor/cancer 111 No tumor/cancer X2 2-t P OR 95% C.I.
+- + -
AA 19 133 6 105 3.754 0.053 2.50 0.90 – 7.28
AG 57 95 52 59 2.309 0.129 0.68 0.40 – 1.15
GG 76 76 53 58 0.130 0.718 1.09 0.65 – 1.84
X2 = Chi-Square, 2-t P = 2-tailed p-value, OR = odds ratio, C.I. = confidence interval
Table 3: CDK4 IVS4-nt40G→A genotype association with cancer
Genotype 46 cancer 204 No cancer X2 2-t P OR 95% C.I.
+- + -
AA 7 39 14 190 3.405 0.060 2.44 0.83 – 7.00
AG 20 26 76 128 0.615 0.433 1.30 0.64 – 2.60
GG 19 27 114 90 3.204 0.073 0.56 0.28 – 1.11
X2 = Chi-Square, 2-t P = 2-tailed p-value, OR = odds ratio, C.I. = confidence intervalJournal of Experimental & Clinical Cancer Research 2009, 28:42 http://www.jeccr.com/content/28/1/42
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ification and genetic screening for obesity-associated
tumor/cancer gene risk variants should be implemented
to prevent tumors and cancer in patients.
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